![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Mylan Laboratories Limited Hyderabad In, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Dacarbazine, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 2016-082 - Rev 01
This Chemical Type CEP, issued on December 18, 2019, remains in force until August 26, 2021, ensuring its reliability within the pharmaceutical industry.
Substance Number 1691 associated with this CEP further emphasizes